Proposed changes to rules governing the commercialization of technologies developed with federal funding prompts significant stakeholder feedback.
Kevin Noonan
Advertisement
Kevin Noonan is partner at McDonnell Boehnen Hulbert & Berghoff LLP and chair of the firm’s biotechnology and pharmaceuticals practice group.
Articles by Kevin Noonan
Proposed changes to rules governing the commercialization of technologies developed with federal funding prompts significant stakeholder feedback.
Cell-based therapies are moving medical treatments forward, but intellectual property uncertainties may delay progress.
Advertisement
Latest Updated Articles
Patenting Prospects for Cell-Based TherapiesSeptember 15th 2017
Advertisement
Advertisement
Trending on BioPharm International
1
BioNTech's BNT113 Misses PFS Goal in Head and Neck Cancer Trial
2
RYZ101 Meets Phase 3 Primary Endpoint in Neuroendocrine Tumors After Lutetium-177 Therapy
3
FDA Rare Disease Framework Initiative: What It Means for Drug and Biologic Development
4
FDA’s ARC Program Highlights Opportunities and Limits of Bayesian Methods in Rare Disease Trials
5